ANNALS OF ONCOLOGY
Scope & Guideline
Empowering discoveries in oncology and hematology.
Introduction
Aims and Scopes
- Clinical Trials and Treatment Outcomes:
The journal extensively covers clinical trials that evaluate the efficacy and safety of new therapies, including immunotherapy, targeted therapy, and chemotherapy, across diverse cancer types. - Precision Oncology:
A significant focus on personalized medicine is evident, with studies exploring genetic profiling, biomarker identification, and the application of next-generation sequencing in tailoring treatment strategies. - Multidisciplinary Approaches:
Emphasizing the importance of collaborative care, the journal highlights research that involves multidisciplinary teams in the management of cancer, integrating inputs from medical oncologists, surgeons, radiologists, and supportive care providers. - Quality of Life and Patient-Centered Care:
Research articles often address the quality of life for cancer patients, exploring the psychosocial aspects of cancer treatment and the impact of various therapies on patient well-being. - Emerging Therapies and Technologies:
The journal features studies on innovative treatment modalities, including the use of artificial intelligence in oncology, novel drug delivery systems, and emerging immunotherapeutic strategies.
Trending and Emerging
- Immunotherapy and Combination Treatments:
There is a significant increase in research focusing on immunotherapeutic agents, particularly in combination with traditional therapies, highlighting the potential for enhanced efficacy in cancer treatment. - Biomarker Development and Liquid Biopsy:
Emerging studies are increasingly focusing on the development of biomarkers and liquid biopsy techniques for early cancer detection, monitoring treatment response, and predicting outcomes. - Artificial Intelligence and Machine Learning Applications:
The integration of AI and machine learning into oncology research is gaining momentum, with studies exploring their applications in diagnostics, treatment planning, and predicting patient outcomes. - Health Disparities and Global Oncology:
Research addressing health disparities in cancer care, particularly in low- and middle-income countries, is becoming more prevalent, emphasizing the need for equitable access to treatment. - Patient-Reported Outcomes and Quality of Life Assessments:
An increasing number of studies are focusing on patient-reported outcomes, emphasizing the importance of incorporating patient perspectives into treatment effectiveness evaluations.
Declining or Waning
- Traditional Chemotherapy Approaches:
There is a noticeable decline in publications focusing solely on traditional chemotherapy regimens, as the field increasingly emphasizes personalized and targeted therapies. - Basic Science Research:
Research that does not directly translate into clinical applications is becoming less prominent, with a stronger emphasis on studies that provide immediate clinical relevance. - Single-Modal Treatment Studies:
The journal has seen a reduction in studies that investigate single-modality treatments, as the trend shifts towards combination therapies that integrate multiple treatment modalities for better efficacy. - Palliative Care Research:
Though still relevant, the volume of publications specifically dedicated to palliative care strategies has decreased, possibly due to a growing focus on curative and life-extending treatments. - Elderly Cancer Patient Studies:
Research specifically targeting elderly cancer populations has seen a decline, as more studies focus on broader demographic groups and the general applicability of treatment strategies.
Similar Journals
LANCET ONCOLOGY
Empowering the oncology community with cutting-edge knowledge.The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.
ONCOLOGY
Advancing cancer research through impactful insights.ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.
Nature Reviews Clinical Oncology
Transforming Cancer Research into PracticeNature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.
Onkologie
Transforming Oncology Research into Clinical Practice.Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.
CLINICAL ONCOLOGY
Fostering Collaboration for Breakthroughs in Cancer TreatmentClinical Oncology is a prestigious peer-reviewed journal published by Elsevier Science London, focusing on the dynamic fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an impressive impact factor reflecting its high-quality research contributions, the journal is ranked in the second quartile for oncology and the first quartile for radiology, underscoring its importance in advancing clinical knowledge and practice. Established in 1975, Clinical Oncology offers researchers, healthcare professionals, and students robust access to cutting-edge studies, reviews, and clinical trials that drive innovation and improve patient care. Based in the United Kingdom, the journal plays a vital role in disseminating significant findings, fostering collaboration, and enhancing education in the biosciences, particularly for those committed to addressing the challenges in cancer treatment and diagnostics. Given its rigorous selection criteria and broad readership, Clinical Oncology remains an essential resource for anyone dedicated to the fields of oncology and radiology.
JAMA Oncology
Pioneering insights in oncology and cancer treatment.JAMA Oncology, published by the American Medical Association, stands at the forefront of cancer research as a premier peer-reviewed journal in the field. With an ISSN of 2374-2437 and an impressive impact factor reflecting its critical insights, the journal has achieved a top-tier position, being ranked in the Q1 quartile for both Cancer Research and Oncology as of 2023, and demonstrating exceptional performance in Medicine as well. Spanning a converged publication period from 2015 through 2024, JAMA Oncology publishes cutting-edge research, clinical trials, and reviews that are pivotal in advancing our understanding and treatment of cancer. The journal's Scopus ranks highlight its global impact, placing it in the top deciles within its categories, ensuring that it remains a vital resource for oncologists, researchers, and students alike. While it currently does not offer open access, JAMA Oncology continues to provide invaluable contributions to the scientific community, promoting a deeper understanding of oncological challenges and breakthroughs.
Clinical Genitourinary Cancer
Inspiring the future of genitourinary cancer care.Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Unveiling Tomorrow's Treatment Options TodayCURRENT TREATMENT OPTIONS IN ONCOLOGY, published by Springer, is a premier academic journal dedicated to disseminating cutting-edge research and advancements in the field of oncology and pharmacology. With a commendable impact factor and ranked in the Q1 category in both oncology and pharmacology for 2023, this journal positions itself as a leading resource for researchers, healthcare professionals, and students alike, offering insightful reviews and original articles that critically evaluate treatment methodologies and clinical practices. Covering a wide scope of topics from early detection to innovative therapies, it fosters the translation of research findings into clinical applications. With its convergence years spanning from 2000 to 2024, CURRENT TREATMENT OPTIONS IN ONCOLOGY continues to be at the forefront of oncological research, providing a platform for scholars to explore the latest therapeutic options and improve patient outcomes. Highly regarded in the academic community, this journal is essential for anyone looking to stay informed about the dynamic landscape of cancer treatment.
Future Oncology
Pioneering discoveries in the fight against cancer.Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Empowering researchers and practitioners in clinical oncology.The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.